Hot Features
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the ... Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02294 | -10.9238095238 | 0.21 | 0.213 | 0.185 | 1783176 | 0.19849399 | CS |
| 4 | -0.09794 | -34.3649122807 | 0.285 | 0.285 | 0.18254 | 2630939 | 0.22186796 | CS |
| 12 | -0.01834 | -8.92891918208 | 0.2054 | 0.2999 | 0.18254 | 3201344 | 0.21571217 | CS |
| 26 | -0.04594 | -19.7167381974 | 0.233 | 0.3389 | 0.18254 | 3036692 | 0.23703047 | CS |
| 52 | -0.08494 | -31.2279411765 | 0.272 | 0.368 | 0.18254 | 3077921 | 0.24372373 | CS |
| 156 | -0.54994 | -74.618724559 | 0.737 | 1.11 | 0.16845 | 2612268 | 0.35881488 | CS |
| 260 | -1.46294 | -88.663030303 | 1.65 | 2.05 | 0.16845 | 2433659 | 0.54542216 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.